Quantcast

Tuesday, August 18, 2009

Fwd: US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease

---------- Forwarded message ----------
From: Drugs.com <sender@list.drugs.com>
Date: 2009/8/18
Subject: US FDA Approves Extavia - the First in a New Portfolio of
Planned MS Therapies from Novartis to Help Patients with This
Devastating Disease
To: mtariqsalman@gmail.com


Sent to you from Drugs.com
New Drug Approval

US FDA Approves Extavia - the First in a New Portfolio of Planned MS
Therapies from Novartis to Help Patients with This Devastating Disease

August 17, 2009

Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has
approved Extavia (interferon beta-1b), the first in a new planned
portfolio of multiple sclerosis (MS) medicines from Novartis to help
patients manage this devastating disease.   Extavia is approved by the
FDA for the treatment of relapsing forms of MS to reduce the frequency
of clinical exacerbations. The therapy is also indicated for patients
who have experienced a first clinical episode of MS...

Read more...

Copyright © 2009 Drugs.com. All rights reserved.

Free Books, powerpoint presentations, teaching tools and resources and drug information